Atlas Trials

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Clinical trial NCT02269163 · COMPLETED

Trial details

NCT number
NCT02269163
Sponsor
Prometic Biotherapeutics, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immunodeficiency
Start date
2016-01-26
Primary completion
2019-01-11
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.